Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

HYPORTH · New approaches in the development of Hypoallergenic implant material in Orthopaedics: steps to personalised medicine

FP7Status: CLOSED1 August 201331 July 2018EU funding €5,282,600

Europe is confronted by a demographic challenge as a decreasing work force has to support an increasing elderly population. The economic risk implied by this burden could be addressed by efforts to achieve an increase in Healthy Life Years. One key element would be to ensure unrestricted mobility for especially the elderly, allowing them to stay at work for longer. Irreversible joint deterioration often requires a joint replacement. Implantation of artificial joints is one of the most successful orthopaedic interventions. However, an increasing number of patients receive revision surgery with these 10 % of these contract an infection and 50 % develop an adverse immune reaction (AIR) to conventional implant material. At the moment the reasons for the development of AIR are inadequately understood. Our proposal contains innovative solutions concerning this problem. A predictive approach using biomarkers will identify patients with risk to develop AIR. These patients will receive hypoallergenic endoprostheses, avoiding AIR to conventional material. Novel hypoallergenic material combinations will be developed in the frame of this consortium by material scientists and implant manufacturer. Via immunological, microbiological and biocompatibility testing the development and production process will be improved constantly. The matching of implant material with the allergenic background of patients will avoid complicated and cost-intensive reverse reactions and is a step towards personalised medicine. A further approach is to achieve a better understanding of mechanisms of AIR, and its faster and easier diagnosis using sensitive diagnostic biomarkers for an accurate differentiation from low-grade infection. Additionally, mathematical modelling of results from different methods will show us the gene regulatory network that leads to an amplification of the adverse immune response triggered by prosthetic implants and will develop predictive models of AIR process.

Consortium · 10 organisations

coordinator

OTTO-VON-GUERICKE-UNIVERSITAET MAGDEBURG

DE · €1,372,151

participant

TARTU ULIKOOL

EE · €900,000

participant

MATHYS AG BETTLACH

CH · €455,199

participant

PROGENIKA BIOPHARMA SA

ES · €750,928

participant

TEKNOLOGISK INSTITUT

DK · €431,376

participant

HUN-REN ENERGIATUDOMANYI KUTATOKOZPONT

HU · €472,856

participant

SIEC BADAWCZA LUKASIEWICZ - INSTYTUT OBROBKI PLASTYCZNEJ

PL · €404,291

participant

HUN-REN TERMESZETTUDOMANYI KUTATOKOZPONT

HU · €117,143

participant

GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG

DE · €104,223

participant

ARTTIC

FR · €274,433

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.